Movicol Apelsin

Macrogol 3350 with electrolytes, the active ingredient in Movicol Apelsin, is an osmotic laxative presented as an oral solution for oral use. It works to increase the water content of the intestinal lumen, facilitating the passage of stool in adults and children suffering from constipation.

GNH USA supplies Movicol Apelsin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics efficiently to meet global distribution networks.

Movicol Apelsin, an osmotic laxative, acts on the gastrointestinal tract to increase intestinal water content and ease stool passage.

Constipation: Relieves occasional constipation by softening stool and promoting regular bowel movements. Chronic idiopathic constipation: Provides long‑term management for patients with persistent constipation not responsive to dietary measures. Opioid‑induced constipation: Helps counteract reduced bowel motility caused by opioid therapy.

Macrogol 3350 with electrolytes may cause several adverse reactions, most of which are mild and transient.

Common Side Effects: - Abdominal bloating: sensation of fullness in the abdomen. - Flatulence: increased gas production. - Nausea: mild feeling of sickness. - Diarrhoea: loose stools occurring after dose. - Stomach cramps: mild cramping discomfort. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe electrolyte imbalance: abnormal sodium or potassium levels requiring medical attention. - Dehydration: excessive fluid loss leading to dizziness or low blood pressure. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Intestinal obstruction worsening: signs of blockage such as severe abdominal pain and vomiting. - Rectal bleeding: unexpected blood in stool.

Before prescribing Movicol Apelsin, consider the following precautions to ensure safe use. - Assess fluid and electrolyte status: evaluate patient’s hydration and electrolyte levels, especially in renal or cardiac disease. - Use with caution in renal impairment: reduced kidney function may affect electrolyte handling. - Monitor in the elderly: older patients are more susceptible to dehydration and electrolyte shifts. - Avoid in intestinal obstruction: the drug can exacerbate blockage. - Do not exceed prescribed dose: higher amounts increase risk of diarrhoea and electrolyte loss. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Macrogol 3350 with electrolytes can interact with certain medicines, altering their effects or increasing adverse risks.

Major Interactions (Avoid): - Concurrent use with other osmotic laxatives: may cause severe diarrhoea and electrolyte depletion. - Combination with loop diuretics: increased risk of hypokalaemia and dehydration. - Co‑administration with lithium: potential for altered lithium levels due to fluid shifts.

Moderate Interactions (Monitor Closely): - Antacids containing aluminium or magnesium: may reduce laxative efficacy. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened risk of renal impairment. - ACE inhibitors or ARBs: monitor kidney function and electrolytes. - Digoxin: watch for electrolyte changes that could affect drug toxicity.